Veradigm appoints former AWS executive Tehsin Syed as chief product and technology officer

CHICAGO - Healthcare data and technology solutions provider Veradigm (OTCMKTS:MDRX) announced Monday the appointment of Tehsin Syed as Chief Product and Technology Officer. The company, currently trading at $4.80 with a market capitalization of $815 million, has seen its stock decline nearly 51% year-to-date according to InvestingPro data.

Syed joins Veradigm from Amazon Web Services (AWS), where he served as General Manager of AWS Health AI. During his tenure at AWS, he oversaw the development of new products for ambient clinical documentation, genomics, medical imaging, and enterprise-grade interoperability solutions.

Prior to AWS, Syed spent over 20 years at Cerner Corporation, where he held the position of Vice President of Strategic Growth Engineering. At Cerner, he led product and platform engineering efforts and played a key role in developing HealtheIntent, a cloud-based population health platform.

"With strategic assets across providers, payers, and life sciences, Veradigm has a strong foundation to turn applied AI into real, daily workflow wins," Syed said in a statement.

Veradigm CEO Donald Trigg expressed confidence in the new appointment, noting that clients and team members would benefit from Syed’s "intelligence, expertise, and collaborative purpose."

The company, which provides healthcare data and technology solutions across the healthcare ecosystem, trades on the over-the-counter market following its delisting from Nasdaq in 2023.

The information in this article is based on a company press release.

In other recent news, Veradigm Inc. announced its second-quarter 2025 revenue is estimated to be between $145 million and $148 million. This represents a 2% decline at the midpoint compared to the same period last year. The company also reported having cash and equivalents of approximately $350 million as of June 30, 2025. This figure marks an increase of about $78 million from the previous quarter. The rise in cash is mainly due to $72 million in net inflows from debt financing and $23 million from investment portfolio activity. These developments are part of Veradigm’s ongoing financial activities. The company also completed a repurchase of convertible notes. These recent developments provide insight into Veradigm’s financial health and strategic decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.